NorthStar Medical Radioisotopes is collaborating with Inhibrx, a biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, the company announced recently.

According to a release, the collaboration will help the companies develop and produce novel radiopharmaceuticals for the treatment of cancer.

“NorthStar is at the forefront of medical radioisotope development and production, and we are pleased to join forces with Inhibrx to combine our technology with their innovative therapeutic candidates to advance the field of targeted alpha therapies,” NorthStar Medical Radioisotopes CEO Stephen Merrick said in a statement.

Under the agreement, NorthStar will support the development of a prespecified number of Inhibrx’s novel biologic products by providing actinium-225 and access to its integrated radiopharmaceutical contract development and manufacturing organization (CDMO) services.

Inhibrx is located in La Jolla, Calif.